宁波优贝德产品网站Unibest
中
Sign in

Pharmaceutical Intermediates

Full official intermediate catalog + key intermediates with CEP / DMF / GMP / cold-chain qualifications and capacity details · each quotable via RFQ

Enquire by CASView API Products →

Featured ProductsProven track record · documents on request

Enter hub →
Others469General Chemicals281Acids116Alcohols30Ketones17Esters43Alkanes17Phenols10
Dealt

Orforglipron intermediates

Sample orders (500 g each) + 0.5 kg repeat order

Dealt 1–4 · latest 2026-09

Documents in progress

Dealt

PINACOLONE

Dual-use item (trade control category)

Dealt 1–4 · latest 2026-01

Documents in progress

Dealt

4-(3-Bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline

CAS 543737-10-6

Dealt 1–4 · latest 2026-07

Documents in progress

Dealt

L-Tyrosine disodium salt, dihydrate

100–199 deals · latest 2026-09

Open for inquiry →

Dealt

D-Glucose Anhydrous

100–199 deals · latest 2026-09

Open for inquiry →

Dealt

Choline chloride

CAS 67-48-1

100–199 deals · latest 2026-09

Open for inquiry →

2026 Key Intermediate Campaigns →

4 target drugs · 7 key intermediates
Lenacapavir3 CAS

Antiviral (HIV-1)

Marketed (US · EU · both treatment and prevention indications)
Orforglipron2 CAS

Metabolic (obesity / type 2 diabetes)

Phase 3 positive · NDA submitted to FDA (under review)
Inavolisib1 CAS

Oncology (breast cancer)

Marketed (FDA-approved first-line combination in Oct 2024)
Osilodrostat1 CAS

Endocrine (Cushing's syndrome)

Marketed (US 2020 · EU 2020 · China 2024)

Patent-cliff opportunities · recommended intermediates

Ranked by opportunity score · source: patent-cliff radarOpen opportunity profile →

semaglutide

68
API0–18 monthsSouth Asia

Intermediate list in preparation — inquiries welcome

Key opportunity markets: India / Bangladesh / Pakistan

olaparib

66
API18–36 monthsNorth America
· 2-Fluoro-5-formylbenzonitrile218301-22-5· 2-Fluoro-5-[(3-oxo-1(3H)-isobenzofuranylidene)methyl]benzonitrile763114-25-6· 2-fluoro-5-((4-oxo-3,4-dihydrophthalazin -1-yl)Methyl)benzoic acid763114-26-7

Key opportunity markets: United States / Canada / Mexico

apixaban

62
Generic FDF0–18 monthsEurope
· 3-Chloro-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one536760-29-9· 3-Morpholino-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one503615-03-0· 1-(4-Aminophenyl)-3-morpholino-5,6-dihydropyridin-2(1H)-one1267610-26-3

Key opportunity markets: United Kingdom / Germany / Italy

sacubitril/valsartan

62
Generic FDF0–18 monthsEast Asia and Oceania

Intermediate list in preparation — inquiries welcome

Key opportunity markets: China / Japan / South Korea

tirzepatide

61
API3–7 yearsEast Asia and Oceania
· AEEA-HCl134979-01-4· AEEA-AEEA1143516-05-5· Boc-AEEA-AEEA1069067-08-8

Key opportunity markets: China / Japan / South Korea

sacubitril/valsartan

61
Generic FDF0–18 monthsNorth America

Intermediate list in preparation — inquiries welcome

Key opportunity markets: United States / Canada / Mexico

Region is inferred coarsely from your browser IP (region-level only, IP not stored). Opportunity scores are internal radar ratings, not a commitment.

By Therapeutic Area of Target Drug

Click a class to filter both sections below; classes follow the target API's primary indication
Metabolic / Endocrine62

Diabetes, obesity, dyslipidemia, NASH and other metabolic diseases

Cardiovascular / Renal58

Hypertension, heart failure, anticoagulation, chronic kidney disease

Oncology / Hematology193

Solid tumours, haematologic malignancies, myeloproliferative diseases

Anti-infectives17

Antiviral, antibacterial, antifungal, HIV / hepatitis

Immunology / Inflammation36

RA, psoriasis, atopic dermatitis, IBD

CNS / Psychiatry46

Epilepsy, pain, depression & anxiety, neurodegeneration

Gastroenterology / Hepatology28

Acid-related, GI motility, diarrhoea, liver disease

Respiratory11

COPD, asthma and other airway diseases

Urology / Women's Health35

Menopausal symptoms, urological conditions

Ophthalmology2

Glaucoma, ocular surface disease

Dermatology0

Skin infection, dermatologic inflammation

Anesthesia / Analgesia0

Local anaesthesia, postoperative analgesia

Allergy4

Allergic rhinitis, urticaria

Animal Health14

Companion-animal ectoparasiticides

Unclassified506

Qualified Key IntermediatesCEP / DMF / GMP / Cold-chain / Capacity / Price-band details

4 items
Product / CASPurity / Impurity profile (redacted)Synthesis route (redacted)CapacityQualificationsPackaging / Cold-chainMOQ / Price bandAction
Orforglipron INT-1 | 5- bromo -4- fluoro -1- methyl indazole
CAS 1784678-61-0 · GLP-1 (metabolic)
Target drug: orforglipron
Highly confidential
≥99.0%
Single impurity ≤0.10% (redacted)
indazole ring construction + N-methylation (redacted summary)2,000 kg/yr
US DMF
5 kg / 25 kg drum
5 kg
US$ 1,850-2,600 / kg
Unibest Nantong cGMP Site
Orforglipron INT-2 | (S)-4- methyl -1,3,2- dioxathiolane -2,2- dioxide
CAS 174953-30-1 · GLP-1 (metabolic)
Target drug: orforglipron
Highly confidential
≥99.0%
Chiral purity ≥99.5% ee (redacted)
chiral diol cyclic sulfate formation (redacted summary)1,500 kg/yr
5 kg drum
5 kg
US$ 980-1,450 / kg
Unibest Nantong cGMP Site
Orforglipron INT-3 | (4- fluoro -3,5- dimethyl phenyl) hydrazine hydrochloride
CAS 2212021-40-2 · GLP-1 (metabolic)
Target drug: orforglipron
Visible after CDA
≥98.5%
Single impurity ≤0.20% (redacted)
diazotisation–reduction (redacted summary)3,000 kg/yr
25 kg drum
10 kg
US$ 560-820 / kg
Unibest Taizhou GMP-like Site
Orforglipron INT-4 | (S)-3- aminobutyronitrile hydrochloride
CAS 1073666-54-2 · GLP-1 (metabolic)
Target drug: orforglipron
Visible after CDA
≥99.0%
Chiral purity ≥99.5% ee (redacted)
asymmetric synthesis + salt formation (redacted summary)2,200 kg/yr
25 kg drum
10 kg
US$ 640-950 / kg
Unibest Taizhou GMP-like Site

Official Intermediate Full CatalogWith CAS numbers · Aggregated by target drug

Total 58 intermediates · covering 255 target drugs
Page 1 / 1
Intermediate nameCAS No.Target drugAction
(R)-2-[[6-(3-Aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-y]methyl]-4-fluorobenzonitrile865759-25-7Alogliptin/ Trelagliptin
(R)-3-(Boc-Amino)piperidine309956-78-3Alogliptin/ Trelagliptin
(R)-3-aminopiperidine dihydrochloride334618-23-4Alogliptin/ Trelagliptin
2-[(6-Chloro-3,4-dihydro-3-methy1-2,4-dioxo-1(2H)-pyrimidinyl)methyl]benzonitrile865758-96-9Alogliptin/ Trelagliptin
2-Cyano-5-fluorobenzyl bromide421552-12-7Alogliptin/ Trelagliptin
2-Cyanobenzyl bromide22115-41-9Alogliptin/ Trelagliptin
6-Chloro-3-methyluracil4318-56-3Alogliptin/ Trelagliptin
6-Chlorouracil4270-27-3Alogliptin/ Trelagliptin
(1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]pheny!]D-glucitol tetraacetate461432-25-7Dapagliflozin
(2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxyMethyl)-2-Methoxytetrahydro-2H-pyran-3,4,5-triol714269-57-5Dapagliflozin
(5-Bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone461432-22-4Dapagliflozin
1-Chloro-2-(4-ethoxybenzyl)-4-iodobenzene1103738-29-9Dapagliflozin
2,3,4,6-Tetrakis-0-trimethylsilyl-D-gluconolactone32384-65-9Dapagliflozin
4-(5-Bromo-2-chlorobenzyl)phenyl ethyl ether461432-23-5Dapagliflozin
5-Bromo-2-chlorobenzoic acid21739-92-4Dapagliflozin
(1R,3aR,7aR)-1-((R)-6-hydroxy-6-Methylheptan-2-yl)-7a-Methylhexahydro-1H-inden-4(2H)-one70550-73-1Eldecalcitol
4H-Inden-4-one, 1-[1,5-dimethyl-5-[(triethylsilyl)oxy]hexyl]octahydro-7a-methyl-, [1R-[1α(R*),3aβ,7aα]]-144848-24-8Eldecalcitol
de-A,B-25-hydroxycholestan-8β-ol66774-84-3Eldecalcitol
Eldecalcitol interMediates200636-42-6Eldecalcitol
Phosphine oxide, [(2Z)-2-[(3R,4R,5R)-2-methylene-3,5-bis[(triethylsilyl)oxy]-4-[3-[(triethylsilyl)oxy]propoxy]cyclohexylidene]ethyl]diphenyl-2189732-17-8Eldecalcitol
Phosphine oxide, [(2Z)-2-[(3R,4R,5R)-3,5-bis[[(1,1-diMethylethyl)diMethylsilyl]oxy]-4-[3-[[(1,1-diMethylethyl)diMethylsilyl]oxy]propoxy]-2-Methylenecyclohexylidene]ethyl]diphenyl-200636-54-0Eldecalcitol
(1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl] -D-glucitol tetraacetate915095-99-7Empagliflozin
(5-Bromo-2-chlorophenyl)(4-fluorophenyl)methanone915095-85-1Empagliflozin
(5-Bromo-2-chlorophenyl)[4-[[(3S)-tetrahydro-3-furanylloxy]phenyllmethanone915095-84-0Empagliflozin
(S)-(+)-3-Hydroxytetrahydrofuran86087-23-2Empagliflozin
(S)-3-[4-[(2-Chloro-5-iodophenyl)methyl]phenoxy]tetrahydrofuran915095-94-2Empagliflozin
(S)-3-[4-[(5-Bromo-2-chlorophenyl)methyl]phenoxy]tetrahydrofuran915095-89-5Empagliflozin
2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone32384-65-9Empagliflozin
4-((5-Bromo-2-chlorophenyl)methyl)phenol864070-18-8Empagliflozin
[(3R)-1-[7-(2-Butynyl)-2,3,6,7-tetrahydro-3-methy1-1-[(4-methy1-2-quinazolinyl)methyl]-2,6-dioxo-1H-purin-8-yll-3-piperidinyllcarbamicacid 1,1-dimethylethyl ester668273-75-4Linagliptin
2-(Chloromethyl)-4-methylquinazoline109113-72-6Linagliptin
3-Methylxanthine1076-22-8Linagliptin
8-Bromo-3-methyl-3,9-dihydro-1H-purine-2,6-dione93703-24-3Linagliptin
8-Bromo-7-(but-2-yn-1-yl)-3-methy1-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione853029-57-9Linagliptin
8-Bromo-7-(but-2-yn-1-yl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione666816-98-4Linagliptin
(2S)-tert-Butyl 3-cyano-2-methyl-4-oxopiperidine-1-carboxylate2212021-56-0Orforglipron
(4-Fluoro-3,5-dimethylphenyl)hydrazine hydrochloride2212021-40-2Orforglipron
(E)-3-(2-(methyl(phenyl)carbamoyl)-1H-indol-5-yl)acrylic acid3047292-97-4Orforglipron
(R,E)-N-methyl-5-(3-oxo-3-(2-oxo-4-phenyloxazolidin-3-yl)prop-1-en-1-yl)-N-phenyl-1H-indole-2-carboxamide3047293-00-2Orforglipron
(R)-4-Benzyl-2-oxazolidinone102029-44-7Orforglipron
(S)-3-Aminobutanenitrile Hydrochloride1073666-54-2Orforglipron
(S)-5-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-N-methyl-N-phenyl-1H-indole-2-carboxamide2212021-79-7Orforglipron
1-(4-fluoro-1-methyl-1H-indazole-5-yl)-3-(2-(4-fluoro-3,5-dimethylphenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-3-yl)-1,3-dihydro-2H-imidazole-2-one hydrochloride3036782-75-6Orforglipron
1-(cyanomethyl)-5-[(4S)-2,2-dimethyloxan-4-yl]-N-methyl-N-phenylindole-2-carboxamide2212021-80-0Orforglipron
1,3,2-Dioxathiolane, 4-Methyl-, 2,2-dioxide, (4R)-1006381-03-8Orforglipron
2H-Imidazol-2-one, 1-[(4S)-2-(4-fluoro-3,5- dimethylpheny1)-4,5,6,7-2H-Imidazol-2-one, 1-[(4S)-2- (4-fluoro-3,5-dimethylpheny1)-4,5,6,7-1H- indazol-5- yl)- 1,3-dihydro-2212022-56-3Orforglipron
3-(3-(4-fluoro-1-methyl-1H-indazole-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester3036782-74-5Orforglipron
5-[(S)-2,2-Dimethyltetrahydro-2H-pyran-4-yl]-1-[(1S,2S)-2-methyl-1-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)cyclopropyl]-1H-indole-2-carboxylic Acid2212021-83-3Orforglipron
5-Bromo-2-fluoro-m-xylene99725-44-7Orforglipron
5-Bromo-4-fluoro-1-methyl-1H-indazole1784678-61-0Orforglipron
5-bromo-N-methyl-N-phenyl-1H-indole-2-carboxamide2860499-50-7Orforglipron
5-Bromoindole-2-carboxylic acid7254-19-5Orforglipron
5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 3-(2,3-dihydro-2-oxo-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-2,4,6,7-tetrahydro-4-methyl-, 1,1-dimethylethyl ester, (4S)-2212021-61-7Orforglipron
H-Indole-2-carboxamide, 1-[(1S,2S)-1-cyano-2-methylcyclopropyl]-N-methyl-N-phenyl-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-2212021-81-1Orforglipron
N-Boc-L-Alaninol79069-13-9Orforglipron
tert-buty1 (S)-3-amino-2-(4- fluoro-3,5- dimethylpheny1)-4- methyl-2,4,6,7-tetrahydro-5H-pyrazoloB ,3-c ]pyridine-5-carboxylate2212021-59-3Orforglipron
tert-butyl 2-(4-fluoro-3,5-dimethylphenyl)-3-(2-oxo-1H-imidazol-3-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carboxylate2212022-03-0Orforglipron
tert-butyl 3-amino-2-(4-fluoro-3,5-dimethylphenyl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carboxylate2212021-41-3Orforglipron